Search results for "From Annals of Internal Medicine"
Diet plus exercise significantly reduced progression to diabetes in Spanish trial
For adults ages 55 to 75 years with metabolic syndrome and overweight or obesity, an intervention that included calorie reduction, the Mediterranean diet, and increased physical activity reduced diabetes incidence by 31% over six years compared to the Mediterranean diet alone.
https://diabetes.acponline.org/archives/2025/09/12/6.htm
12 Sep 2025
Canagliflozin safe, tolerable in kids, adolescents, manufacturer study finds
A phase 3 trial found significantly greater reductions in HbA1c levels in children and adolescents 10 years of age and older who were randomized to canagliflozin versus placebo.
https://diabetes.acponline.org/archives/2025/08/08/7.htm
8 Aug 2025
Dementia risk similar with GLP-1 receptor agonists, DPP-4 inhibitors
A target trial emulation that matched Medicare patients who started glucagon-like peptide-1 (GLP-1) receptor agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors did not find a significant difference in their dementia risk.
https://diabetes.acponline.org/archives/2025/08/08/6.htm
8 Aug 2025
Annals On Call: Expenditures after bariatric surgery
Annals On Call is a podcast focusing on a clinically influential article published in Annals of Internal Medicine. A recent episode discussed the health expenditures of patients with diabetes who undergo bariatric surgery.
https://diabetes.acponline.org/archives/2025/05/09/7.htm
9 May 2025
Only 4 of 14 diabetes performance measures adequate, ACP position paper says
The College's Performance Measurement Committee recently reviewed 14 current performance measures for diabetes that are relevant to internal medicine.
https://diabetes.acponline.org/archives/2025/05/09/6.htm
9 May 2025
ED visits for semaglutide adverse events rare, study suggests
The majority of ED visits related to taking semaglutide were attributed to gastrointestinal complications and hypoglycemia.
https://diabetes.acponline.org/archives/2025/04/11/6.htm
11 Apr 2025
In the Clinic, Ideas and Opinions address diabetes
A recent In the Clinic reviewed hyperglycemia in hospitalized patients, and an opinion article discussed misuse of race in interpretation of HbA1c levels.
https://diabetes.acponline.org/archives/2024/12/13/8.htm
13 Dec 2024
Medicare coverage of semaglutide would be costly
Covering semaglutide for patients who are overweight and have cardiovascular disease could cost Medicare an additional $34 to $145 billion annually, researchers estimated.
https://diabetes.acponline.org/archives/2024/09/13/7.htm
13 Sep 2024
Little difference in dementia risk with SGLT-2s vs. dulaglutide
Older patients with type 2 diabetes starting sodium-glucose cotransporter-2 (SGLT-2) inhibitors had an estimated difference of less than a percentage point in five-year risk of clinical onset of dementia compared with those starting the glucagon-like peptide-1 receptor agonist dulaglutide, a South Korean study found.
https://diabetes.acponline.org/archives/2024/09/13/6.htm
13 Sep 2024
Use of GLP-1 receptor agonists rose steeply in past decade, study finds
A million U.S. patients, mostly women, started taking glucagon-like peptide-1 (GLP-1) receptor agonists between 2011 and 2023, according to an analysis of medical records across the country.
https://diabetes.acponline.org/archives/2024/08/09/6.htm
9 Aug 2024
Latest Beyond the Guidelines, In the Clinic target diabetes
An endocrinologist and a nephrologist discuss appropriate care for type 2 diabetes and chronic kidney disease, and the evidence supporting type 2 diabetes prevention and treatment are reviewed.
https://diabetes.acponline.org/archives/2024/06/14/6.htm
14 Jun 2024
SGLT-2 inhibitors associated with improved outcomes in stage 5 CKD patients
Patients with type 2 diabetes and stage 5 chronic kidney disease (CKD) had lower risk of progressing to dialysis or having a cardiovascular event if they took sodium-glucose cotransporter-2 (SGLT-2) inhibitors, a study found.
https://diabetes.acponline.org/archives/2024/05/10/6.htm
10 May 2024
State caps on insulin costs for commercially insured didn't increase insulin use
Limits on out-of-pocket costs did lower patients' insulin expenses, but the effect was mostly limited to those with health savings accounts, a pre-post comparison among U.S. states found.
https://diabetes.acponline.org/archives/2024/04/12/6.htm
12 Apr 2024
Annals On Call: Type 1 diabetes
Annals On Call is a podcast focusing on a clinically influential article published in Annals of Internal Medicine. A recent episode discussed the age at which U.S. adults with type 1 diabetes are being diagnosed.
https://diabetes.acponline.org/archives/2023/12/08/8.htm
8 Dec 2023
Diabetes more common in low-income middle-aged people, rising among higher-income group
Between 1999 and 2020, rates of diabetes and obesity held steady in lower-income middle-aged adults in the U.S., while these risk factors rose among the higher-income middle-aged, from 7.8% to 14.9% and 33.0% to 44.0%, respectively.
https://diabetes.acponline.org/archives/2023/12/08/7.htm
8 Dec 2023
Finerenone works by quickly lowering albuminuria, analysis finds
Reductions in the urine albumin-to-creatinine ratio within four months were responsible for 84% of the treatment effect of finerenone on kidney outcomes and 37% of that on cardiovascular outcomes, according to an industry-funded four-year analysis of trials in patients with chronic kidney disease and type 2 diabetes.
https://diabetes.acponline.org/archives/2023/12/08/6.htm
8 Dec 2023
Weekly insulin icodec superior to daily insulin analogues in latest manufacturer trial
Patients with type 2 diabetes who used weekly insulin icodec and a dosing app had greater reductions in HbA1c levels than similar patients randomized to start a daily insulin analogue with a traditional dosing strategy.
https://diabetes.acponline.org/archives/2023/10/13/6.htm
13 Oct 2023
Insulin costs, diabetes and testosterone
An Ideas and Opinions piece explained some of the factors behind insulin prices, and a meta-analysis looked at testosterone levels in men with diabetes.
https://diabetes.acponline.org/archives/2023/09/08/6.htm
8 Sep 2023
Crowdfunding campaigns often focus on overall cost of diabetes, rarely mention insulin
A quarter of fundraisers for patients with diabetes reported that the patient had insurance, and many mentioned noncovered costs such as lost wages, healthy food, and diabetic alert dogs.
https://diabetes.acponline.org/archives/2023/07/14/6.htm
14 Jul 2023
ACP Journal Club: SGLT-2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetes
The results of this meta-analysis of sodium-glucose cotransporter-2 (SGLT-2) inhibitors highlight the opportunity for internists, nephrologists, endocrinologists, and cardiologists to collaborate to expand use of the drug class, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/03/10/7.htm
10 Mar 2023